DNA-PK inhibitors

Details DNA-PK inhibitors DNA-PK inhibitors

2007-06-05

2007-06-05

Solola, Taofiq (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S459000, C544S151000, C549S399000

Reexamination Certificate

active

10486816

ABSTRACT:
The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1and R2are independently hydrogen, an optionally substituted C1-7alkyl group, C3-20heterocyclyl group, or C5-20aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR4and O, O and CR′4and NR″4and N, where the unsaturation is in the appropriate place in the ring, and where one of R3and R4or R′4is an optionally substituted C3-20heteroaryl or C5-20aryl group, and the other of R3and R4or R′4is H, or R3and R4or R″4together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.

REFERENCES:
patent: 4954518 (1990-09-01), Takano et al.
patent: 5252735 (1993-10-01), Morris
patent: 5284856 (1994-02-01), Naik et al.
patent: 5302613 (1994-04-01), Morris
patent: 5703075 (1997-12-01), Gammill et al.
patent: 5733920 (1998-03-01), Mansuri et al.
patent: 5922755 (1999-07-01), Tanaka et al.
patent: 6348311 (2002-02-01), Kastan et al.
patent: 6387640 (2002-05-01), Kastan et al.
patent: 2004/0002492 (2004-01-01), Smith et al.
patent: 2004/0023968 (2004-02-01), Martin et al.
patent: 2006/0106025 (2006-05-01), Smith et al.
patent: 2006/0178361 (2006-08-01), Hummersone et al.
patent: 0 610 519 (1994-08-01), None
patent: 0 635 268 (1995-01-01), None
patent: 0 640 339 (1995-03-01), None
patent: 0 641 566 (1995-03-01), None
patent: 0 648 492 (1995-04-01), None
patent: 0 658 343 (1995-06-01), None
patent: 1303724 (1973-01-01), None
patent: 2 302 021 (1997-01-01), None
patent: WO 90/06921 (1990-06-01), None
patent: WO 91/19707 (1991-12-01), None
patent: WO 92/00290 (1992-01-01), None
patent: WO 95/29673 (1995-11-01), None
patent: WO 96/01108 (1996-01-01), None
patent: WO 97/15658 (1997-05-01), None
patent: WO 97/18323 (1997-05-01), None
patent: WO 98/55602 (1998-12-01), None
patent: WO 98/56391 (1998-12-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 01/53266 (2001-07-01), None
patent: WO 02/20500 (2002-03-01), None
patent: WO 02/056912 (2002-07-01), None
patent: WO 03/024949 (2003-03-01), None
patent: WO 03/093261 (2003-04-01), None
patent: WO 03/034997 (2003-05-01), None
patent: WO 03/035618 (2003-05-01), None
patent: WO 03/070726 (2003-08-01), None
patent: 2006032869 (2006-03-01), None
Ismail, I.H. et al., “SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization,” Oncogene (2004) 23:873-883.
Kashishian, A. et al., “DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer,” Mol. Cancer Ther. (2003) 2:1257-1264.
Lau et al., “Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase,” Nature Cell Biology (2005) 7:493-500.
Muller, C. et al., “DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards,” Blood (1998) 92:2213-2219.
Sirzen, F. et al., “DNA-dependent protein kinase content and activity in lung carcinoma cell lines: Correlation with intrinsic radiosensitivity,” Eur. J. Cancer (1999) 35:111-116.
Abraham, Robert T., “Cell cycle checkpoint signaling through the ATM and ATR kinases,”Genes&Dev., 15: 2177-2196 (2001).
Archer, S. et al., “Ring-Hydroxylated Analogues of Lucanthone as Antitumore Agents,”J. Med. Chem., 25, 220-227 (1982).
Brown, P.O., “Integration of retroviral DNA,”Curr Top Microbiol Immunol., 157:19-48 (1990).
Chiosis, G, et al. “LY294002-geldanamycin heterodiamers as selective inhibitors of the PI3K and PI3k-related family”, Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 7, Apr. 9, 2001 pp. 909-913, XP004232522.
Daniel, Rene, et al., “Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses,”Mol. Cell Biol, 21:4, 1164-1172 (2001).
Durocher, Daniel, and Jackson, Stephen P., “DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?,”Curr Opin Cell Biol., 13:225-231 (2001).
Giroux, A., et al, “One pot biaryl synthesis via in situ boronate formation,”Tet. Lett., 38:22, 3841-3844 (1997).
Griffin, et al., “Selective Benzopyranone and Pyrimido [2,1-a]isoquinolin-4-one Inhibitors of DNA-Dependent Protein Kinase: Synthesis, Structure—Activity Studies, and Radiosensitization of a Human Tumor Cell Line in Vitro”,J. Med. Chem., 2005, 48, 569-585.
Haselhorst, Dorte, et al., “Development of cell lines stably expressing human immunodeficiency virus type 1 proteins for studies in encapsidation and gene transfer,”J Gen Virol, 79: 231-237 (1998).
Herzog, Karl-Heinz et al., “Requirement for ATM in ionizing radiation-induced cell death in the developing central nervous system,”Science, 280: 1089-1091 (1998).
Hickson, Ian, et al, “Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM,”Cancer Research64, Dec. 15, 2004, 9152-9159.
Ishiyama, T. et al., “Synthesis of arylboronates via the palladium(0)-catalyzed cross-coupling reaction of tetra(alkoxo)diborons with aryl triflates,”Tett. Lett., 38:19, 3447-3450 (1997).
Keith, Curtis T. and Schreiber, Stuart L., “PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints,”Science, 270: 50-51 (1995).
Leahy, et al., “Identfication of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone librariest”,Bioorganic&Medicinal Chemistry Letters14 (2004) 6083-6087.
Metcalfe, Judith A. et al., “Accelerated telomere shortening in ataxia telangiectasia,”Nature Genetics, 13: 350-353 (1996).
Mlotkowska, B.L. et al., “Two-dimensional NMR studies of 2-substituted thioxanthene sulfoxides,”J. Heterocyclic Chem., 28: 731-736 (Apr.-May 1991).
Naldini, Luigi et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,”Science, 272: 263-267 (1996).
Sarkaria, Jann N. et al., “Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine,”Cancer Res., 59: 4375-4382 (1999).
Savitsky, Kinneret et al., “A single ataxia telangiectasia gene with a product similar to P1-3 kinase,”Science, 268:1749-1753 (1995).
Shiloh, Yosef, “ATM and ATR: networking cellular responses to DNA damage,”Curr. Opin. Genet. Dev., 11:71-77 (2001).
Willmore, et al., “A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia,”Blood, Jun. 15, 2004, vol. 103, No. 12, 4659-4665.
Zakian, Virginia A., “ATM-related genes: What do they tell us about functions of the human gene?”Cell, 82:685-687 (1995).
Banin, S., et al, “Enhanced phosphorylation of p53 by ATM in response to DNA damage,”Science, 1998, vol. 281, pp. 1674-1677.
Bantick, J.R., et al., “Synthesis of 2-aminochromones,”J. Heterocyclic Chem., 1981, vol. 18, pp. 679-684.
Berge, et al., “Pharmaceutically acceptable salts,”J. Pharm. Sci., 1977, vol. 66, pp. 1-19.
Bettoni, et al., “Synthesis and absolute configuration of substituted morpholines,”Tetrahedron, 1980, vol. 36, pp. 409-415.
Boyd, J., et al., “The Chemistry of the ‘insoluble red’ woods,”J. Chem. Soc., 1948, pp. 174-176.
Buon, C., et al., “Synthesis of 3-substituted and 2,3-disubstituted-4H-1,4-Benzoxa

Affiliated with

Also associated with

Rating

DNA-PK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA-PK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA-PK inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3874020